Zobrazeno 1 - 10
of 136
pro vyhledávání: ''
Autor:
Yuan Wu, Chester Kao, Tian Zhang, Neal Ready, Michael B. Datto, Eric Powers, Jeffrey M. Clarke, John H. Strickler, Michelle F. Green
Publikováno v:
Clinical Lung Cancer. 22:500-509
Introduction A high tumor mutational burden (TMB) (≥10 mut/Mb) has been associated with improved clinical benefit in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI) and is a tumor agnostic indication for pembroliz
Autor:
Cristina Merkhofer, Renato G. Martins, Scott D. Ramsey, Keith D. Eaton, Bernardo H. L. Goulart
Publikováno v:
Clin Lung Cancer
Introduction The impact of clinical trial participation on overall survival is unclear. We hypothesized that enrollment in a therapeutic drug clinical trial is associated with longer overall survival in patients with metastatic non-small cell lung ca
Publikováno v:
Clinical Lung Cancer. 22:e808-e816
Background Conflicting data exists regarding the benefit of prophylactic cranial irradiation (PCI) in patients with extensive-stage small-cell lung cancer (ES-SCLC). We sought to retrospectively review outcomes of patients within our network with ES-
Autor:
Megan E. Daly, Angel Moran, Tokihiro Yamamoto, Brandon A. Dyer, Yichuan Wang, Stephen S.F. Yip
Publikováno v:
Clinical lung cancer, vol 22, iss 5
IntroductionWe investigated whether adding computed tomography (CT) and/or 18F-fluorodeoxyglucose (18F-FDG) PET radiomics features to conventional prognostic factors (CPFs) improves prognostic value in locally advanced non-small cell lung cancer (NSC
Autor:
Christopher J. Rivard, Anders Berglund, Simon Ekman, Hui Yu, Linnea La Fleur, Johan Botling, Patrick Micke, Steinar Solberg, Odd Terje Brustugun, Fred R. Hirsch
Publikováno v:
Clinical Lung Cancer. 22:e555-e562
Background Recently, anti–programmed cell death 1 (PD-1) and anti–programmed cell death ligand 1 (PD-L1) immunotherapies have yielded promising outcomes for patients with advanced non–small cell lung cancer (NSCLC) and led to great interest in
Autor:
Peter J. Kneuertz, Morgan Fitzgerald, Desmond M. D’Souza, Mahmoud Abdel-Rasoul, Robert E. Merritt
Publikováno v:
Clinical Lung Cancer. 22:e574-e583
Background Stage I non–small-cell lung cancer (NSCLC) is potentially curable with surgical resection. Significant proportions of patients may still experience recurrence and death despite undergoing curative surgery. This study describes predictive
Autor:
Noboru Oriuchi, Ryohei Yamamoto, Yukitoshi Satoh, Akihiro Ichikawa, Satoshi Shiozawa, Nobuhiro Nishizawa, Hideki Endoh
Publikováno v:
Clinical Lung Cancer. 22:218-224
Introduction 2-[18F] Fluoro- d -deoxyglucose (FDG) positron emission tomography (PET) is a relevant diagnostic procedure for staging lung cancer. However, accurate evaluation of lymph node metastases by PET is controversial because of false-positive
Autor:
Maria Júlia Gonçalves de Mello, Luiz Claudio Santos Thuler, Gustavo Telles da Silva, Guilherme Jorge Costa, Carlos Gil Ferreira, Anke Bergmann
Publikováno v:
Clinical Lung Cancer. 22:e313-e319
Lung cancer is the principal cause of cancer-related deaths worldwide; however, there has been controversy as to whether there is a difference in survival rate according to gender in Brazil. The aim of the present study, therefore, was to compare the
Autor:
Stefan Janssen, Andrea Wittig, Guido Hildebrandt, Eleni Gkika, Fabian Lohaus, E. Schrade, Detlef Imhoff, Lorenz Uhlmann, Peter Hass, Christoph Henkenberens, Denise Bernhardt, Hans-Ulrich Herold, Irina Sackerer, Oliver Blanck, Davide Scafa, Juliane Hörner-Rieber, Arndt-Christian Mueller, Robert Krempien, H. Kahl, Hans Th. Eich, Matthias Guckenberger, Marciana Nona Duma, Stefan Friedrich Lautenschläger, Sabine Gerum, Katrin Jurianz, Cordula Petersen
Publikováno v:
Clinical Lung Cancer. 20:e667-e677
This multicenter study aims to analyze outcome as well as early versus late patterns of recurrence following pulmonary stereotactic body radiotherapy (SBRT) for patients with oligometastatic non-small-cell lung cancer (NSCLC).This analysis included 3
Publikováno v:
Clinical Lung Cancer. 20:e620-e630
Two main categories of epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) patients are deletions in exon 19 and L858R in exon 21. Treatments of advanced NSCLC patients with these mutations are well documented, and